GCFRX
Price
$10.05
Change
-$0.01 (-0.10%)
Updated
Nov 14 closing price
VASIX
Price
$15.57
Change
-$0.00 (-0.00%)
Updated
Nov 14 closing price
Ad is loading...

GCFRX vs VASIX

Header iconGCFRX vs VASIX Comparison
Open Charts GCFRX vs VASIXBanner chart's image
Nationwide Inv Dest Cnsrv R
Price$10.05
Change-$0.01 (-0.10%)
VolumeN/A
CapitalizationN/A
Vanguard LifeStrategy Income I
Price$15.57
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
GCFRX vs VASIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GCFRX vs. VASIX commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GCFRX is a Sell and VASIX is a Hold.

FUNDAMENTALS
Fundamentals
VASIX has more cash in the bank: 3.97B vs. GCFRX (292M). VASIX pays higher dividends than GCFRX: VASIX (3.30) vs GCFRX (3.02). GCFRX was incepted earlier than VASIX: GCFRX (21 years) vs VASIX (30 years). GCFRX is a more actively managed with annual turnover of: 8.48 vs. VASIX (4.00). GCFRX has a lower initial minimum investment than VASIX: GCFRX (0) vs VASIX (3000). VASIX (9.73) and GCFRX (9.44) have marching annual gain over last year. GCFRX return over 5 years is better than : 9.54 vs. VASIX (6.04).
GCFRXVASIXGCFRX / VASIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence21 years30 years-
Gain YTD4.6284.486103%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets292M3.97B7%
Annual Yield % from dividends3.023.3092%
Returns for 1 year9.449.7397%
Returns for 3 years-2.51-4.7153%
Returns for 5 years9.546.04158%
Returns for 10 years18.1227.1067%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DEC13.370.50
+3.89%
Diversified Energy Company plc
NLY19.620.14
+0.72%
Annaly Capital Management
BEAM27.50-0.44
-1.57%
Beam Therapeutics
UFI5.68-0.12
-2.07%
UNIFI
ONCT1.14-0.07
-5.87%
Oncternal Therapeutics